PFO
MRNA icon

Pathstone Family Office’s Moderna MRNA Stock Holding History

Pathstone Family Office’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$1.07M Buy
10,404
+5,651
+119% +$630K 0.01% 681
2023
Q2 		$610K Sell
4,753
-870
-15% -$116K 0.01% 665
2023
Q1 		$912K Sell
5,623
-14,039
-71% -$2.32M 0.01% 473
2022
Q4 		$2.72M Buy
19,662
+7,317
+59% +$1.2M 0.02% 417
2022
Q3 		$1.46M Buy
12,345
+8,546
+225% +$1.3M 0.01% 553
2022
Q2 		$543K Buy
3,799
+963
+34% +$138K 0.01% 543
2022
Q1 		$489K Buy
2,836
+651
+30% +$110K 0.01% 559
2021
Q4 		$554K Sell
2,185
-1,760
-45% -$515K 0.01% 521
2021
Q3 		$1.52M Buy
3,945
+862
+28% +$318K 0.04% 207
2021
Q2 		$725K Sell
3,083
-2,317
-43% -$414K 0.02% 361
2021
Q1 		$707K Buy
5,400
+5,180
+2,355% +$751K 0.02% 276
2020
Q4 		$23K Buy
220
+120
+120% +$12.1K ﹤0.01% 662
2020
Q3 		$7K Buy
+100
New +$6.97K ﹤0.01% 638
2020
Q2 		– Sell
-300
Closed -$9K – 881
2020
Q1 		$9K Buy
+300
New +$6.9K ﹤0.01% 548

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Pathstone Family Office's MRNA Position: Q3 2023 in Review

Pathstone Family Office increased its Moderna (MRNA) stake by 119% in Q3 2023, buying an estimated $630K and bringing the position to 10,404 shares worth $1.07M. The position accounts for 0.01% of the portfolio, ranked #681.

Pathstone Family Office first reported a position in MRNA in Q1 2020 and has held it in 14 quarters since. The position peaked at $2.72M in Q4 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Pathstone Family Office held 10,404 shares of Moderna worth $1.07M as of Q3 2023.
  • Pathstone Family Office bought 5,651 Moderna shares in Q3 2023, an estimated $630K.
  • Moderna made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #681 holding.
  • Pathstone Family Office first reported a position in Moderna in Q1 2020 and has held it in 14 quarters since.
  • Pathstone Family Office's Moderna position peaked at $2.72M in Q4 2022.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.